| Literature DB >> 32989210 |
Kapil Gururangan1,2, Marisa K Holubar2.
Abstract
BACKGROUND Nosocomial diarrhea affects 12% to 32% of hospitalized patients. Before the development of the Clostridium difficile cytotoxin assay in the 1970s, Staphylococcus aureus was frequently implicated as a cause of hospital-acquired infectious colitis, particularly in association with recent antibiotic therapy or abdominal surgery. Decreased utilization of stool culture has reduced the recognition of S. aureus as a rare, but historically important, cause of enterocolitis. CASE REPORT An 81-year-old man with no recent history of travel, exposure to potential infectious sources (e.g., sick contacts, animals, undercooked foods), or antibiotic or proton-pump inhibitor use was admitted for a Whipple procedure (expanded intraoperatively with total pancreatectomy, splenectomy, and portal vein resection) for stage III pancreatic adenocarcinoma. On postoperative day (POD) 5, the patient developed large-volume watery diarrhea that did not improve with tube feeding cessation and oral pancreatic enzyme replacement. He subsequently became clinically septic on POD10, and workup revealed severe radiographic sigmoid and rectal colitis and methicillin-resistant S. aureus (MRSA) bacteremia. Polymerase chain reaction testing for C. difficile was negative twice (POD5 and POD12). He was diagnosed with MRSA proctocolitis and improved with initiation of oral and intravenous vancomycin. CONCLUSIONS We describe a case of staphylococcal enterocolitis, a previously common cause of nosocomial diarrhea that has become increasingly underappreciated since the advent of culture-independent stool testing for C. difficile. Increased awareness of this entity, especially when Clostridium assays are negative, may guide more effective treatment of hospital-acquired infection.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32989210 PMCID: PMC7532527 DOI: 10.12659/AJCR.922521
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
Published cases and reports of Staphylococcus aureus enterocolitis in adults.
| Gururangan and Holubar (this report) | 2016 | USA | 1 | Yes | AA, PS | CD test: (–) NAAT BCx: (+) MRSA SCx: (–) for SA ANS: (+) MRSA | PO+IV vancomycin, IV daptomycin | Patient developed MRSA bacteremia prior to diagnosis of proctocolitis, switched from IV vancomycin to IV daptomycin due to acute renal injury Outcome: Survival |
| Ackermann et al. [ | 2005 | Germany | 25 | No | AA | CD test: (–) EIA in 24% SCx: (+) SA, 60% also (+) CD | NS | SCx (+) for SA in 25 of 89 (28%) patients with AA diarrhea Outcome: NS |
| Altemeier et al. [ | 1963 | USA | 155 | NT | AA | CD test: NT SCx: (+) SA | Various anti-staphylococcal antibiotics, probiotics | 58 patients (37%) were PS Enterocolitis found in 17 of 32 autopsies Outcome: Survival in 107, death in 48 |
| Asha et al. [ | 2006 | UK | 10 | Yes | AA | CD test: (–) cytotoxin assay SCx: (+) MRSA | NS | ≥1 pathogen detected in 735 of 4659 (16%) stool specimens; 10 (0.2%) grew SA; 591 (13%) had a (+) CD cytotoxin assay Outcome: NS |
| Avery et al. [ | 2015 | USA | 1 | Yes | AA | CD test: (–) NAAT SCx: (+) MRSA | Vancomycin, probiotics | Final diagnosis was toxin-negative CD Outcome: Survival |
| Bae et al. [ | 2011 | South Korea | 1 | Yes | AA | CD test: (–) NAAT LGIS: severe mucosal edema and (+) MRSA | Vancomycin | Subsequent lymphocytic colitis Outcome: Survival |
| Bergevin et al. [ | 2017 | Canada | 1 | Yes | AA | CD test: (–) EIA SCx: (+) MRSA LGIS: diffuse acute colitis | Vancomycin | ANS (+) Outcome: NS |
| Bettenworth et al. [ | 2013 | Germany | 1 | Yes | IBD | CD test: NT SCx: (–) for CD LGIS: acute Crohn’s colitis and (+) MRSA | Linezolid | ANS (–) and perianal swab (+) for MRSA Outcome: Survival |
| Boyce and Havill [ | 2005 | USA | 11 | Yes | AA | CD test: (–) EIA SCx: (+) MRSA | Vancomycin | Patients with MRSA on SCx had greater average stool volume and number per day Patients with ET (–) MRSA had fewer days of diarrhea and stools per day Outcome: NS |
| Boyce et al. [ | 2005 | USA | 151 | Yes | NS | CD test: NS (see notes) SCx: (+) MRSA | NS | 1543 patients tested for CD with EIA, 159 (10%) (+)EIA and 151 (9.8%) (+) SCx for MRSA Number of patients with both MRSA and CD was not reported Outcome: NS |
| Brown et al. [ | 1953 | USA | 2 | NT | AA, PS | CD test: NT Autopsy: PM colitis and (+) SA | Terramycin, streptomycin, sulfisoxazole, aureomycin | Both patients were also reported by Wakefield and Sommers [ |
| Cheng et al. [ | 2006 | Australia | 1 | Yes | AA, PS | CD test: (–) cytotoxin assay SCx: (+) MRSA | Vancomycin | Outcome: Survival |
| Chubachi et al. [ | 1993 | Japan | 1 | Yes | Neutropenia | CD test: NT SCx and BCx: (+) MRSA | Vancomycin | Patient developed sepsis and respiratory distress Outcome: Survival |
| Clarke and Baidoo [ | 2012 | USA | 1 | Yes | Healthcare worker | SCx: (+) MRSA, (–) CD LGIS: pancolitis | Vancomycin | Outcome: Survival |
| Cope et al. [ | 1953 | USA | 1 | No | AA, PS | CD test: NT BCx: (+) SA Autopsy: PM colitis and (+) SA | Aureomycin | Outcome: Death |
| Dalal and Urban [ | 2008 | USA | 2 | Yes | AA | CD test: (–) cytotoxin assay BCx: no growth SCx: (+) MRSA | Vancomycin, piperacillin-tazobactam | Both patients presented with sepsis Outcome: Survival in 2 |
| Dickinson et al. [ | 1980 | UK | 2 | No | AA, IBD | CD test: NT SCx: (+) SA LGIS: normal | Steroids | CD culture and cytotoxin assay were not sought Outcome: Survival in 2 |
| Estifan et al. [ | 2019 | USA | 1 | Yes | AA | CD test: (–) NS SCx: (+) MRSA | Vancomycin, trimethoprim-sulfamethoxazole | Patient had type 1 diabetes and presented in diabetic ketoacidosis Imaging showed acute appendicitis Outcome: Survival |
| Fairlie and Kendall [ | 1953 | USA | 5 | NT | AA, PS | CD test: NT Autopsy (+) SA | Penicillin, dihydro-streptomycin, aureomycin, oxytetracycline | Outcome: Survival in 2, death in 3 |
| Flemming and Ackermann [ | 2007 | Germany | 198 | Yes/No | AA, hospital stay ≥72 hours | CD test: (+) EIA in 25 SCx: (+) MSSA (85%) or MRSA (15%) | NS | 121 of 2727 (4%) (+) for CD 198 of 2727 (7%) (+) for SA, of which 29 (15%) were MRSA Outcome: NS |
| Froberg et al. [ | 2004 | USA | 1 | Yes | AA | CD test: (+) cytotoxin assay BCx: (+) MRSA SCx: (+) MRSA and CD Autopsy: 2 PM lesions, one with SA and one with CD | Vancomycin, metronidazole, amikacin | Autopsy also showed colonic perforation Outcome: Survival |
| Furukawa et al. [ | 2015 | Japan | 1 | Yes | AA, PS | CD test: (–) EIA SCx: (+) MRSA Pathology: (+) SA | Vancomycin | Emergent laparotomy was performed, revealed cecum perforation Outcome: Survival |
| Gravet et al. [ | 1999 | France | 60 | Yes/No | AA | CD test: (+) cytotoxin assay and culture in 4 patients SCx: (+) SA, MRSA in 92% | Vancomycin | Outcome: NS |
| Kalakonda et al. [ | 2016 | USA | 1 | Yes | None | CD test: (–) NAAT BCx: no growth SCx: (+) MRSA LGIS: PM colitis | Vancomycin | Patient presented in sepsis Initial SCx had no growth, repeat SCx (+) for MRSA Outcome: Survival |
| Kodama et al. [ | 1997 | Japan | 14 | Yes | AA, PS | CD test: NT SCx: (+) MRSA | Vancomycin | 13 of 14 (93%) strains were ET-producing Outcome: NS |
| Konishi et al. [ | 1997 | Japan | 31 | Yes | PS | CD test: NT SCx: (+) MRSA, 4 also grew CD in small numbers | Vancomycin | IV antibiotics were given to 19 of 31 patients, 6 received IV vancomycin Outcome: Survival in 31 |
| Kotler et al. [ | 2007 | USA | 1 | No | HIV, AA | CD test: (–) cytotoxin assay SCx: (+) SA LGIS: acute colitis | Vancomycin, cefepime, octreotide | Patient developed toxic-shock syndrome, SA was ET-producing Outcome: Survival |
| Lane et al. [ | 2018 | USA | 1 | Yes | AA | CD test: (–) NAAT SCx: (+) MRSA UCx: (+) MRSA | PO+IV vancomycin | Urine and stool MRSA isolates were found to be genetically identical Outcome: Survival |
| Lepley and Smith [ | 1957 | USA | 16 | NT | AA, PS | CD test: NT SCx: (+) SA | Chloramphenicol, erythromycin | Outcome: NS |
| Lieverse et al. [ | 2001 | Netherlands | 2 | No | Sick contact | CD test: NT BCx: no growth Gastric fluid, elbow aspirate: (+) SA | Ciprofloxacin or gentamicin | Husband with elbow wound growing SA, wife changed his bandages Wife expired, laparotomy showed multiple bowel perforations Outcome: Death in 2 |
| Lo and Borchardt [ | 2009 | USA | 5 | Yes | AA | CD test: (–) EIA SCx: (+) MRSA | Vancomycin | One patient improved without antibiotics Outcome: Survival in 5 |
| McPherson et al. [ | 2005 | UK | 1 | Yes | AA, PS | CD test: (–) EIA SCx: (+) MRSA Wound culture: (+) MRSA LGIS: normal | Vancomycin, doxycycline | Outcome: Survival |
| Ogawa et al. [ | 2014 | Japan | 1 | Yes | AA | CD test: (–) NAAT SCx: (+) MRSA BCx: (+) MRSA Synovial fluid: (+) MRSA | Vancomycin | Presented in sepsis, which resolved prior to diarrhea onset Septic arthritis diagnosed followed treatment Outcome: Survival |
| Okada et al. [ | 2018 | Japan | 1 | Yes | PS | SCx: (–) CD, (+) MRSA | Vancomycin, metronidazole, rifampicin | MRSA strain was resistant to vancomycin Outcome: Survival |
| Pressly et al. [ | 2016 | USA | 1 | Yes | IBD | CD test: (–) NAAT SCx: (+) MRSA LGIS: PM colitis | Vancomycin | Patient reported eating deviled eggs prior to symptom onset Outcome: Survival |
| Rhee et al. [ | 2004 | USA | 1 | Yes | AA | CD test: (–) EIA SCx: (+) MRSA | Vancomycin | Outcome: Survival |
| Rogers et al. [ | 2019 | USA | 1 | Yes | AA | CD test: (–) EIA SCx: (+) MRSA | PO+IV vancomycin, piperacillin-tazobactam | Patient diagnosed with acute diverticulitis Outcome: Survival |
| Rothman et al. [ | 2018 | USA | 1 | Yes | HIV, AA | CD test: NS SCx: (+) MRSA BCx: (+) MRSA | Vancomycin, cefepime, azithromycin | Presented with enterocolitis in the setting of newly diagnosed acute myeloid leukemia Initial SCx (+) for MRSA felt to be insignificant until symptoms persisted and patient developed septic shock Outcome: Death |
| Shah et al. [ | 2016 | USA | 1 | No | AA, IBD | CD test: (–) cytotoxin assay SCx: (+) SA | Vancomycin | Outcome: Survival |
| Schiller et al. [ | 1998 | USA | 1 | Yes | AA | CD test: (–) EIA BCx: no growth SCx: (+) MRSA | Vancomycin | Outcome: Survival |
| Sizemore et al. [ | 2012 | USA | 1 | Yes | AA, PS | CD test: (–) NAAT SCx: (+) MRSA | Vancomycin, mupirocin, probiotic | ANS (+) Outcome: Survival |
| Sonpal et al. [ | 2010 | USA | 1 | Yes | IDB | CD test: (–) cytotoxin assay SCx: (+) MRSA | Vancomycin | Outcome: Survival |
| Speare [ | 1954 | USA | 8 | NT | AA, PS | CD test: NT SCx: (+) SA | Aureomycin, magnamycin, sulfadiazine | Outcome: Survival in 3, death in 5 |
| Takesue et al. [ | 1993 | Japan | 10 | Yes | PS | CD test: NT Sputum, drain, stool, skin, blood culture: (+) MRSA in 138 samples | NS | 10 of 503 (2%) PS patients developed MRSA enteritis Outcome: Survival in 10 |
| Takeuchi et al. [ | 2001 | Japan | 17 | Yes | AA, PS | CD test: NT Gastric juice, drain output, or SCx: (+) MRSA | Vancomycin | Outcome: Survival in 15, death in 2 |
| Taylor et al. [ | 1993 | UK | 1 | Yes | AA, IBD | CD test: (–) EIA SCx: (+) MRSA, (–) CD | Vancomycin | Outcome: Survival |
| Thakkar and Agrawal [ | 2010 | USA | 1 | NT | AA | CD test: NT SCx: (+) SA LGIS: chronic active necrotizing colitis | Levofloxacin, metronidazole, proton-pump inhibitor | Exploratory laparotomy showed toxic megacolon, and Gram stain of surgical specimens showed gram-positive cocci in clusters Discharged without postoperative antibiotic therapy Outcome: Survival |
| Wakefield and Sommers [ | 1953 | USA | 3 | NT | AA, PS | CD test: NT Autopsy: intestinal lining and heart BCx (+) SA | Streptomycin, terramycin, sulfisoxazole, aureomycin, penicillin | Two patients were also reported by Brown et al. [ |
| Wallace et al. [ | 1965 | USA | 7 | NT | AA, PS | CD test: NT SCx: (+) SA | Vancomycin | SA strains resistant to penicillin G Outcome: Survival in 7 |
| Watanabe et al. [ | 2001 | Japan | 13 | Yes | AA, PS | CD test: (–) EIA Sputum, pharynx, nasal, gastric juice, or stool culture: (+) MRSA in all 45 samples | NS | 12 of 13 (92%) patients had MRSA isolates from respiratory and digestive cultures with identical or near-identical molecular characteristics Outcome: NS |
| Wei et al. [ | 2015 | China | 5 | Yes | AA, IBD, PS | SCx: (–) CD Gastric juice culture: (+) MRSA | Fecal microbiota transplantation | Outcome: Survival in 5 |
| Yoshida et al. [ | 1992 | Japan | 2 | Yes | AA, PS | CD test: NT SCx: (+) MRSA | Vancomycin | Outcome: Survival in 2 |
Includes reports published in English language; for reports published in Japanese, please see the systematic review by Iwata and colleagues [8]. AA – antibiotic-associated; ANS – anterior nares screen for MRSA; BCx – blood culture; CD – Clostridium difficile; EIA – enzyme immunoassay for C. difficile antigen (glutamate dehydrogenase) and toxin; LGIS – lower gastrointestinal scope, including colonoscopy or sigmoidoscopy; ET – S. aureus enterotoxin; IBD – inflammatory bowel disease; IV – intravenous; MRSA – methicillin-resistant S. aureus; N – number of patients with S. aureus; NAAT – nucleic acid amplification test (including polymerase chain reaction); NS – not specified; NT – not tested; PM – pseudomembranous; PO – per os (oral administration); PS – postsurgical; SA – S. aureus; SCx – stool culture; UK – United Kingdom; USA – United States of America.